Jan 12, 2014 Press Release for Alnylam
Alnylam Acquires Investigational RNAi Therapeutic Assets from Merck
Jan 12, 2014
- Strategic Transaction Positions RNAi Assets for Future Advancement through Alnylam's Commitment to RNAi Therapeutics -
"We are excited to enter this agreement with Merck. We believe the
acquisition of
Under the agreement, in exchange for acquiring the stock of
"Scientists at Merck have made important contributions to the
advancement of RNAi therapeutics particularly in the design and
engineering of RNAi molecules with enhanced drug-like properties," said
Merck built upon the acquisition of
The transaction is subject to customary closing conditions, including the requirements under the Hart Scott-Rodino Antitrust Improvements Act.
About
Alnylam is a biopharmaceutical company developing novel therapeutics
based on RNA interference, or RNAi. The company is leading the
translation of RNAi as a new class of innovative medicines with a core
focus on RNAi therapeutics as genetic medicines, including programs as
part of the company's "Alnylam 5x15TM" product strategy.
Alnylam's genetic medicine programs are RNAi therapeutics directed
toward genetically defined targets for the treatment of serious,
life-threatening diseases with limited treatment options for patients
and their caregivers. These include: patisiran (ALN-TTR02), an
intravenously delivered RNAi therapeutic targeting transthyretin (TTR)
for the treatment of TTR-mediated amyloidosis (ATTR) in patients with
familial amyloidotic polyneuropathy (FAP); ALN-TTRsc, a subcutaneously
delivered RNAi therapeutic targeting TTR for the treatment of ATTR in
patients with familial amyloidotic cardiomyopathy (FAC); ALN-AT3, an
RNAi therapeutic targeting antithrombin (AT) for the treatment of
hemophilia and rare bleeding disorders (RBD); ALN-AS1, an RNAi
therapeutic targeting aminolevulinate synthase-1 (ALAS-1) for the
treatment of hepatic porphyrias including acute intermittent porphyria
(AIP); ALN-CC5, an RNAi therapeutic targeting complement component C5
for the treatment of complement-mediated diseases; ALN-PCS, an RNAi
therapeutic targeting PCSK9 for the treatment of hypercholesterolemia;
ALN-AAT, an RNAi therapeutic targeting alpha-1-antitrypsin (AAT) for the
treatment of AAT deficiency liver disease; ALN-TMP, an RNAi therapeutic
targeting TMPRSS6 for the treatment of beta-thalassemia and
iron-overload disorders; and ALN-ANG, an RNAi therapeutic for the
treatment of genetic forms of mixed hyperlipidemia and severe
hypertriglyceridemia, amongst other programs. As part of its "Alnylam
5x15" strategy, as updated in early 2014, the company expects to have
six to seven genetic medicine product candidates in clinical development
- including at least two programs in Phase 3 and five to six programs
with human proof of concept - by the end of 2015. The company's
demonstrated commitment to RNAi therapeutics has enabled it to form
major alliances with leading companies including Merck, Medtronic,
Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, Cubist,
GlaxoSmithKline, Ascletis, Monsanto, The Medicines Company, and Genzyme,
a Sanofi company. In
Alnylam Forward-Looking Statements
Various statements in this press release concerning Alnylam's future
expectations, plans and prospects, including without limitation,
Alnylam's views with respect to the potential value of the assets being
acquired and its ability to further its efforts to build a new class of
medicines, the potential timing of the closing of the transaction, as
well as the potential for RNAi therapeutics, including the programs in
its "Alnylam 5x15" pipeline, constitute forward-looking statements for
the purposes of the safe harbor provisions under
Vice
President, Investor Relations and
or
Spectrum
202-955-6222 x2597
Source:
News Provided by Acquire Media
For Media Inquiries, please contact:
Christine Akinc
Chief Corporate Communications Officer media@alnylam.com 617-682-4340
For Investor Inquiries, please contact:
Josh Brodsky
VP, Investor Relations & Corporate Communications investors@alnylam.com 617-551-8276
MEDIA KIT
Essential assets and documents related to Alnylam